Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

FLIGHT CENTRIC AIR TRAFFIC CONTROL WITH AIRSTREAMS. A NEW APPROACH TO TRAFFIC FLOW MODELING

Autor: Dohy, D., J-L, Raoul, Georges Mykoniatis, Mora-Camino, F.

Publikováno v: 9th International Conference on Experiments/Process/System Modeling/Simulation/Optimization
9th International Conference on Experiments/Process/System Modeling/Simulation/Optimization, Jul 2021, Athens, Greece
HAL

International audience; This paper is relative to FC2A project that addresses a challenging approach for an environmentally friendly, more agile Air Traffic Management (ATM) framework by combining Flight Centric ATC and Airstream concepts. The day-to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b2d09554b6a6cc44c9e28869002cb6fa
https://hal-enac.archives-ouvertes.fr/hal-03313086

Hepatocellular carcinoma: What are the palliative care options?

Autor: G. Capodano, J. L. Raoul, M. Gilabert

Publikováno v: Oncologie. 19:184-187

Les soins de confort doivent etre instaures precocement chez les patients ayant un carcinome hepatocellulaire sur cirrhose. En effet, leur qualite de vie est souvent alteree. Les troubles du sommeil peuvent beneficier de mesures hygieniques simples,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9236abb4815342b6987f089185caaa9c
https://doi.org/10.1007/s10269-017-2714-4

Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma

Autor: J L, Raoul, S, Faivre, J S, Frenel, L, Rimassa

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 30(1)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9217c6bee3aec1947a0020807be10e10
https://pubmed.ncbi.nlm.nih.gov/30358824

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer

Autor: R. Lamy, Patrice Viens, J-L. Raoul, Rémy Largillier, Mohamed Gasmi, J.F. Seitz, Benjamin Esterni, J. R. Delpero, Hervé Perrier, Olivier Turrini, Laurence Moureau-Zabotto, X. Tchiknavorian, M Giovannini, E. Francois, Dominique Genre, A. Goncalves, D. Re, Marine Gilabert, Laetitia Dahan

Publikováno v: Annals of Oncology. 23:2799-2805

Background Sorafenib is an oral anticancer agent targeting Ras-dependent signaling and angiogenic pathways. A phase I trial demonstrated that the combination of gemcitabine and sorafenib was well tolerated and had activity in advanced pancreatic canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f759a652be19ef663edd6fe132a07cc
https://doi.org/10.1093/annonc/mds135